$5.61 Million in Sales Expected for ADMA Biologics Inc (ADMA) This Quarter

Wall Street brokerages forecast that ADMA Biologics Inc (NASDAQ:ADMA) will report sales of $5.61 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for ADMA Biologics’ earnings, with estimates ranging from $5.00 million to $6.50 million. ADMA Biologics posted sales of $4.73 million in the same quarter last year, which suggests a positive year over year growth rate of 18.6%. The business is scheduled to announce its next earnings results on Friday, November 2nd.

According to Zacks, analysts expect that ADMA Biologics will report full year sales of $21.35 million for the current fiscal year, with estimates ranging from $18.00 million to $23.00 million. For the next year, analysts anticipate that the business will report sales of $55.86 million per share, with estimates ranging from $29.00 million to $111.10 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover ADMA Biologics.

Several analysts have issued reports on the stock. BidaskClub raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Oppenheimer set a $13.00 price objective on shares of ADMA Biologics and gave the company a “buy” rating in a research report on Sunday, August 5th. Chardan Capital assumed coverage on shares of ADMA Biologics in a research report on Monday, July 30th. They issued a “buy” rating and a $10.00 price objective for the company. ValuEngine raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Thursday, July 26th. Finally, Maxim Group increased their price objective on shares of ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, July 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. ADMA Biologics presently has an average rating of “Buy” and a consensus target price of $9.50.

In related news, CEO Adam S. Grossman purchased 52,301 shares of the firm’s stock in a transaction dated Friday, June 8th. The stock was acquired at an average price of $4.78 per share, with a total value of $249,998.78. Following the completion of the transaction, the chief executive officer now owns 32,527 shares of the company’s stock, valued at $155,479.06. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jerrold B. Grossman purchased 20,921 shares of the firm’s stock in a transaction dated Friday, June 8th. The shares were bought at an average cost of $4.78 per share, with a total value of $100,002.38. Following the transaction, the director now directly owns 98,007 shares of the company’s stock, valued at approximately $468,473.46. The disclosure for this purchase can be found here. Insiders have bought 78,222 shares of company stock valued at $373,901 in the last three months. Corporate insiders own 16.90% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in ADMA. Spark Investment Management LLC acquired a new stake in shares of ADMA Biologics during the first quarter worth approximately $102,000. AMP Capital Investors Ltd acquired a new stake in shares of ADMA Biologics during the second quarter worth approximately $109,000. Element Capital Management LLC acquired a new stake in shares of ADMA Biologics during the first quarter worth approximately $118,000. Renaissance Technologies LLC acquired a new stake in shares of ADMA Biologics during the second quarter worth approximately $132,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of ADMA Biologics during the second quarter worth approximately $160,000. 56.38% of the stock is owned by institutional investors and hedge funds.

NASDAQ:ADMA traded up $0.02 during trading hours on Monday, hitting $5.74. The stock had a trading volume of 139,000 shares, compared to its average volume of 199,996. The company has a quick ratio of 8.88, a current ratio of 10.65 and a debt-to-equity ratio of 0.79. ADMA Biologics has a 1-year low of $2.01 and a 1-year high of $6.86. The company has a market capitalization of $265.12 million, a price-to-earnings ratio of -3.02 and a beta of 2.40.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Story: What does EPS mean?

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply